Skip to main content
. Author manuscript; available in PMC: 2019 Dec 31.
Published in final edited form as: Am J Gastroenterol. 2010 Feb 9;105(5):1133–1139. doi: 10.1038/ajg.2010.9

Table 3.

Primary indication for testing for human anti-chimeric antibodies and infliximab concentrations

Indication, n (%) N =155
Loss of response 76 (49)
Partial response on initiation 34 (22)
Autoimmune/delayed hypersensitivity reaction 16 (10)
Primary non-response 8 (5)
Reintroduction after drug holiday 7 (5)
Endoscopic/CTE recurrence 6 (4)
Acute infusion reaction 5 (3)
Unclear reason 3 (2)

CTE, computed tomography enterography.